Innovent Biologics

2000 Alameda de las Pulgas, suite 120
San Mateo
United States

Show jobs for this employer

About Innovent Biologics

Innovent Biologics (USA), Inc. is the US headquarters of one of the largest and well-known biotechnology companies based in China focused on developing innovative therapeutics in oncology, autoimmune, metabolic and other major diseases.  We have a small start-up team environment situated within a ~$11 billion dollar Market Cap parent company with almost 3000 employees.

Established in 2011, Innovent has developed a fully-integrated platform which includes research & development, manufacturing, clinical development, and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 23 innovative assets in the fields of oncology, autoimmune, metabolic diseases and other major therapeutic areas, with sixteen in clinical development, five in Phase 3 clinical trials, and will have 3 biologics approved this year, plus a PD-1 inhibitor, Tyvyt®, officially approved for marketing in China late 2018. 

On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong.  The company has strategic collaborations with Eli Lilly and Company, Adimab, Incyte, Hanmi, Coherus, Alector, and other international pharmaceutical companies. For more information, please visit:

3 articles with Innovent Biologics